Higrotona (Chlortalidone)

Higrotona is indicated for the oral treatment of two primary conditions that involve excess fluid retention and elevated arterial pressure.

• Management of hypertension, either as monotherapy or in combination with other antihypertensive agents.
• Reduction of edema associated with congestive heart failure, liver cirrhosis, or renal disease.
• Adjunct therapy to control fluid overload in patients with nephrotic syndrome.
• Support of potassium‑sparing diuretics when a stronger diuretic effect is required.
• Use in clinical protocols that require long‑term blood‑pressure control and volume reduction.

• Chlortalidone acts by inhibiting the sodium‑chloride cotransporter (NCC) located in the distal convoluted tubule of the nephron. Blocking this transporter reduces reabsorption of Na+ and Cl−, leading to increased urinary excretion of sodium, chloride, and water. The resulting decrease in extracellular fluid volume lowers cardiac preload and systemic vascular resistance, which contributes to its antihypertensive effect. The diuretic action also modestly enhances calcium reabsorption, which may be beneficial in certain bone‑metabolism contexts.

Like other thiazide‑like diuretics, Higrotona may be associated with a range of adverse reactions that vary in frequency and severity.

Common

• Increased urination and mild electrolyte shifts such as low potassium or sodium.
• Dizziness or light‑headedness, especially after the first doses.
• Headache, fatigue, or muscle cramps.
• Elevated blood glucose levels in susceptible individuals.
• Mild increase in serum uric acid, which can precipitate gout attacks.
• Transient increase in cholesterol or triglyceride levels.

Serious

• Severe electrolyte disturbances, including hyponatremia, hypokalemia, or hypercalcemia.
• Acute kidney injury manifested by sudden rise in serum creatinine.
• Allergic reactions such as rash, pruritus, or angioedema.
• Pancreatitis presenting with abdominal pain and elevated enzymes.
• Severe photosensitivity reactions with skin blistering on sun exposure.

When prescribing Higrotona, clinicians should evaluate patient history and monitor specific parameters to minimize risks.

• Assess renal function before initiation and periodically during therapy.
• Monitor serum electrolytes, especially potassium, sodium, and calcium, at baseline and after dose changes.
• Use caution in patients with a history of gout, diabetes, or hyperlipidemia.
• Avoid in individuals with severe hepatic impairment or anuria.
• Counsel patients about standing up slowly to reduce orthostatic dizziness.
• Consider dose adjustment in the elderly due to increased sensitivity to volume depletion.
• Review concomitant medications that may potentiate electrolyte loss.

Higrotona can affect the pharmacokinetics or pharmacodynamics of several other agents; awareness of these interactions helps maintain therapeutic safety.

Avoid

• Concurrent use with other potent diuretics (e.g., loop diuretics) that may cause excessive volume depletion.
• Combination with lithium, which can increase lithium toxicity.
• Co‑administration with NSAIDs that may blunt diuretic efficacy and impair renal function.

Use with caution

• ACE inhibitors or ARBs, which may enhance the risk of hyperkalemia and renal impairment.
• Antidiabetic drugs, as volume loss can affect glucose control.
• Calcium‑channel blockers, which may increase the hypotensive effect.
• Anticoagulants, because changes in plasma volume can alter drug concentrations.